FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592877210> ?p ?o ?g. }

• W2592877210 endingPage "e014579" @default.
• W2592877210 startingPage "e014579" @default.
• W2592877210 abstract "<h3>Objectives</h3> Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) explored the impact of gender, risk factors and anticoagulant (AC) treatment on 1-year outcomes in patients with non-valvular atrial fibrillation (NVAF). <h3>Design</h3> GARFIELD-AF is a prospective non-interventional registry. <h3>Setting</h3> Investigator sites (n=1048) are representative of the care settings/locations in each of the 35 countries. <h3>Participants</h3> Patients ≥18yrs with newly diagnosed (≤6 weeks9 duration) NVAF and ≥1 investigator-determined stroke risk factors. <h3>Main outcome measures</h3> Event rates per 100 person-years were estimated from the Poisson model and HRs and 95% CIs calculated. <h3>Results</h3> Of 28 624 patients (women 44.4%; men 55.6%) enrolled, there were more elderly (≥75 years) women (46.9%) than men (30.4%). All-cause mortality rates per 100 person-years (95% CI) for women and men were 4.48 (4.12 to 4.87) and 4.04 (3.74 to 4.38), respectively, stroke/systemic embolism (SE) (1.62 (1.41 to 1.87) and 1.17 (1.01 to 1.36)) and major bleeding (0.93 (0.78 to 1.13) and 0.79 (0.66 to 0.95)). After adjustment for baseline risk factors in treated and untreated patients, HRs (95% CI) for women (relative to men) for stroke/SE rates were 1.3-fold higher in women (HR 1.30 (1.04 to 1.63)), and similar for major bleeding (1.13 (0.85 to 1.50)) and all-cause mortality (1.05 (0.92 to 1.19)). Antithrombotic treatment patterns in men and women were almost identical. 63.8% women and 62.9% men received AC± antiplatelets. Relative to no AC treatment, the reduction in stroke/SE rates with AC treatment was greater (p=0.01) in men (HR 0.45 (0.33 to 0.61)) than women 0.77 (0.57 to 1.03). All-cause mortality reduction with AC treatment was similar (women: 0.65 (0.54 to 0.77); men: 0.57 (0.48 to 0.68)). The risk of major bleeding when treated with AC versus no AC was 2.33 (1.41 to 3.84) in men and 1.86 (1.16 to 2.99) in women (p value=0.53). <h3>Conclusions</h3> Women have a higher risk of stroke/SE and the reduction in stroke/SE events rates with AC treatment is less in women than in men. <h3>Trial registration number</h3> NCT01090362." @default.
• W2592877210 created "2017-03-16" @default.
• W2592877210 creator A5009167101 @default.
• W2592877210 creator A5021368492 @default.
• W2592877210 creator A5022363985 @default.
• W2592877210 creator A5030339706 @default.
• W2592877210 creator A5035533211 @default.
• W2592877210 creator A5036209306 @default.
• W2592877210 creator A5041974328 @default.
• W2592877210 creator A5043881451 @default.
• W2592877210 creator A5056162349 @default.
• W2592877210 creator A5060633896 @default.
• W2592877210 creator A5064682115 @default.
• W2592877210 creator A5065723634 @default.
• W2592877210 creator A5072026482 @default.
• W2592877210 creator A5079494067 @default.
• W2592877210 creator A5088406700 @default.
• W2592877210 date "2017-03-01" @default.
• W2592877210 modified "2023-10-16" @default.
• W2592877210 title "Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry" @default.
• W2592877210 cites W152570996 @default.
• W2592877210 cites W1631460485 @default.
• W2592877210 cites W1976210867 @default.
• W2592877210 cites W1984896511 @default.
• W2592877210 cites W1987730138 @default.
• W2592877210 cites W2011188945 @default.
• W2592877210 cites W2020560609 @default.
• W2592877210 cites W2023143117 @default.
• W2592877210 cites W2034814979 @default.
• W2592877210 cites W2036605610 @default.
• W2592877210 cites W2062731392 @default.
• W2592877210 cites W2081669586 @default.
• W2592877210 cites W2089222520 @default.
• W2592877210 cites W2092492353 @default.
• W2592877210 cites W2092504136 @default.
• W2592877210 cites W2110571427 @default.
• W2592877210 cites W2121394112 @default.
• W2592877210 cites W2124243510 @default.
• W2592877210 cites W2124601103 @default.
• W2592877210 cites W2124882362 @default.
• W2592877210 cites W2126653348 @default.
• W2592877210 cites W2132505348 @default.
• W2592877210 cites W2136273801 @default.
• W2592877210 cites W2147018083 @default.
• W2592877210 cites W2148056560 @default.
• W2592877210 cites W2151074096 @default.
• W2592877210 cites W2154464108 @default.
• W2592877210 cites W2155301214 @default.
• W2592877210 cites W2155397983 @default.
• W2592877210 cites W2283863574 @default.
• W2592877210 cites W2509795914 @default.
• W2592877210 cites W3004050106 @default.
• W2592877210 cites W35889501 @default.
• W2592877210 cites W4238531734 @default.
• W2592877210 cites W77543033 @default.
• W2592877210 doi "https://doi.org/10.1136/bmjopen-2016-014579" @default.
• W2592877210 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5353285" @default.
• W2592877210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28264833" @default.
• W2592877210 hasPublicationYear "2017" @default.
• W2592877210 type Work @default.
• W2592877210 sameAs 2592877210 @default.
• W2592877210 citedByCount "28" @default.
• W2592877210 countsByYear W25928772102017 @default.
• W2592877210 countsByYear W25928772102018 @default.
• W2592877210 countsByYear W25928772102019 @default.
• W2592877210 countsByYear W25928772102020 @default.
• W2592877210 countsByYear W25928772102021 @default.
• W2592877210 countsByYear W25928772102022 @default.
• W2592877210 countsByYear W25928772102023 @default.
• W2592877210 crossrefType "journal-article" @default.
• W2592877210 hasAuthorship W2592877210A5009167101 @default.
• W2592877210 hasAuthorship W2592877210A5021368492 @default.
• W2592877210 hasAuthorship W2592877210A5022363985 @default.
• W2592877210 hasAuthorship W2592877210A5030339706 @default.
• W2592877210 hasAuthorship W2592877210A5035533211 @default.
• W2592877210 hasAuthorship W2592877210A5036209306 @default.
• W2592877210 hasAuthorship W2592877210A5041974328 @default.
• W2592877210 hasAuthorship W2592877210A5043881451 @default.
• W2592877210 hasAuthorship W2592877210A5056162349 @default.
• W2592877210 hasAuthorship W2592877210A5060633896 @default.
• W2592877210 hasAuthorship W2592877210A5064682115 @default.
• W2592877210 hasAuthorship W2592877210A5065723634 @default.
• W2592877210 hasAuthorship W2592877210A5072026482 @default.
• W2592877210 hasAuthorship W2592877210A5079494067 @default.
• W2592877210 hasAuthorship W2592877210A5088406700 @default.
• W2592877210 hasBestOaLocation W25928772101 @default.
• W2592877210 hasConcept C126322002 @default.
• W2592877210 hasConcept C127413603 @default.
• W2592877210 hasConcept C164705383 @default.
• W2592877210 hasConcept C187212893 @default.
• W2592877210 hasConcept C2777185221 @default.
• W2592877210 hasConcept C2779161974 @default.
• W2592877210 hasConcept C2780645631 @default.
• W2592877210 hasConcept C2908647359 @default.
• W2592877210 hasConcept C71924100 @default.
• W2592877210 hasConcept C73269764 @default.
• W2592877210 hasConcept C78519656 @default.
• W2592877210 hasConcept C99454951 @default.

• next